<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098199</url>
  </required_header>
  <id_info>
    <org_study_id>597102-3</org_study_id>
    <nct_id>NCT03098199</nct_id>
  </id_info>
  <brief_title>AMH and Dosing Regimens for Initial IVF Stimulation Protocols</brief_title>
  <official_title>AMH and Dosing Regimens for Initial IVF Stimulation Protocols</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive Specialists of New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive Specialists of New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study on a hormone in women called anti-mullerian hormone (AMH) an
      indicator of the amount of egg reserve in the ovaries. The research involves a blood draw to
      determine the AMH level. This knowledge will help the investigators decide a dosage of
      gonadotropins, the hormones used to stimulate the production of more than one egg for use in
      an in vitro fertilization (IVF) cycle. The amount of gonadotropin given has to be tailored to
      each individual participant. The investigators can use information about the participant and
      the hormone levels to determine this dosage and the chances of becoming pregnant as a result
      of IVF treatment. The reason the investigators are doing this research is to find out if
      basing the gonadotropin dosage solely on the participant's AMH level will give the
      investigators a better result than the previous method based on age and other hormone levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background / Rationale Anti-Müllerian Hormone (AMH) has been established as a valuable
      biomarker of ovarian reserve. It is a glycoprotein produced by granulosa cells of the ovary;
      it regulates the development of the primary follicle while inhibiting further recruitment of
      other surrounding follicles. Day 3 FSH and basal antral follicle count have traditionally
      been used to assess ovarian reserve and while they remain excellent predictors of poor
      ovarian response, they have not been shown to predict IVF success rates. Given the
      association between AMH and ovarian reserve, it has been proposed that AMH level can be used
      to predict ovarian response to gonadotropin stimulation and also, IVF success rates. An
      inverse relationship between AMH and total gonadotropin dosage has previously been
      demonstrated. As such, the concept of tailoring stimulation protocols to the patient's
      potential for oocyte production based on AMH level has gained favor. Individualization allows
      the practitioner to use the minimum dosage of medication required for maximum response, while
      limiting the risk of ovarian hyperstimulation syndrome. The question becomes how to determine
      the dosage of medication required for each AMH level and what effect will this have on
      clinical outcomes?

      Hypothesis 1) Knowledge of AMH level used to determine medication dosage at the start of the
      stimulation cycle will result in a higher oocyte yield at the time of retrieval, higher
      clinical pregnancy rate, and higher live birth rate.

      2) Knowledge of AMH level used to determine initial medication dosage at the start of the
      stimulation cycle will result in a fewer number of dosage changes mid-cycle.

      3) Knowledge of AMH level prior to the start of a stimulation cycle will result in the use of
      a different initial stimulation dose compared to cycles in which the AMH is unknown.

      4) Knowledge of AMH level used to determine medication dosage prior to the start of the
      stimulation cycle will result in a lower rate of ovarian hyperstimulation syndrome (OHSS).
      (Defined as &gt;=20 oocytes/follicles) 5) Knowledge of AMH level used to determine medication
      dosage prior to the start of the stimulation cycle will result in a lower rate of cancelled
      cycles.

      Methods and Procedures. The AMH level for all patients will be assessed at the initial
      fertility evaluation for each patient.

      Patients will undergo controlled ovarian hyperstimulation (COH) with a GnRH antagonist
      protocol. They will begin COH on day 3 of their menstrual cycle or they may need to begin
      with approximately one week of oral contraceptives. After one week, the patients will stop
      taking oral contraceptives if their ovaries appear quiescent on transvaginal ultrasound and
      their serum E2 levels are low. These patients will then begin COH three days later.
      Gonadotropin dosage will be determined at the start of the cycle by AMH level.

      Dosages will be adjusted, beginning on the third day of gonadotropins, based on clinical
      response, determined by serum hormone levels and transvaginal ultrasound of the ovaries
      throughout the cycle. The patient will begin taking the GnRH antagonist, Ganirelix or
      Cetrotide, when the lead follicle measures ≥14mm on transvaginal ultrasound. Patients will be
      triggered with Lupron, hCG, or both when the lead follicle measures ≥20mm on transvaginal
      ultrasound. All medications are administered via subcutaneous injections.

      Transvaginal ultrasound-guided oocyte retrieval will be performed 36 hours after the trigger
      medication(s) is administered. Cycles with a poor ovarian response, defined as &lt;3 follicles
      and/or a peak estradiol level &lt;600 pg/mL, will be canceled.

      Patients will undergo culture day 5 embryo transfer; number of embryos transferred will be
      according to ASRM guidelines. If the patient exhibits symptoms of OHSS, she will discontinue
      luteal phase support and will not have an embryo transfer, and all good quality blastocyst
      mbryos will be cryopreserved. All patients eligible for embryo transfer will continue the
      luteal phase support protocol until the serum hCG pregnancy test 14 days post-retrieval. If
      the serum hCG is &lt;5 mIU/mL, luteal phase support will be discontinued. If the serum hCG is ≥5
      mIU/mL, Estrace will continue to be taken until 8 weeks gestation and Endometrin or
      intramuscular progesterone in oil will continue to be used until 10 weeks gestation. At this
      point, patient is released to the care of the obstetrician. The patient or the obstetrician
      will be contacted for pregnancy outcome data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>two years</time_frame>
    <description>Clinical pregnancy rate is defined as the number of pregnancies with the presence of an intrauterine gestational sac seen on transvaginal ultrasound by six weeks gestation divided by the number of completed embryo transfers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oocyte yield</measure>
    <time_frame>two years</time_frame>
    <description>number of follicles produced</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>AMH&lt;1.5, 300IU Gonal-F + 150 IU Menopur</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage at 300IU Gonal-F + 150IU Menopur</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage of 225IU Gonal-F + 75IU Menopur</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>start dosage of 150IU Gonal-F and 75IU Menopur</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMH &gt;=7.0, 75IU Gonal-F+75U Menopur</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>start dosage of 75IU Gonal-F and 75U Menopur</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300IU Gonal-F</intervention_name>
    <description>&lt;1.5 AMH group</description>
    <arm_group_label>AMH&lt;1.5, 300IU Gonal-F + 150 IU Menopur</arm_group_label>
    <other_name>follitropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150IU Menopur</intervention_name>
    <description>&lt;1.5 AMH group</description>
    <arm_group_label>AMH&lt;1.5, 300IU Gonal-F + 150 IU Menopur</arm_group_label>
    <other_name>menotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>225IU Gonal-F</intervention_name>
    <description>1.6-2.5 AMH group</description>
    <arm_group_label>AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75IU Menopur</intervention_name>
    <description>1.6-2.5 AMH group 2.6-6.9 AMH group &gt;7.0 AMH group</description>
    <arm_group_label>AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur</arm_group_label>
    <arm_group_label>AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur</arm_group_label>
    <arm_group_label>AMH &gt;=7.0, 75IU Gonal-F+75U Menopur</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150IU Gonal-F</intervention_name>
    <description>2.6-6.9 AMH group</description>
    <arm_group_label>AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75IU Gonal-F</intervention_name>
    <description>&gt;7.0 AMH group</description>
    <arm_group_label>AMH &gt;=7.0, 75IU Gonal-F+75U Menopur</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first cycle of IVF with transfer of fresh embryo

        Exclusion Criteria:

          -  use of non-autologous oocytes; prior diagnosis of premature ovarian failure or
             diminished ovarian reserve; BMI&gt;= 40; cryopreservation cycles; smokers; use of
             PGS/PGD; use of surgically retrieved sperm or patients with severe male factor; and
             oocyte- or embryo-banking cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Sung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive Specialists of New York</affiliation>
  </overall_official>
  <reference>
    <citation>Anderson RA, Nelson SM, Wallace WH. Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas. 2012 Jan;71(1):28-33. doi: 10.1016/j.maturitas.2011.11.008. Epub 2011 Nov 26. Review.</citation>
    <PMID>22119275</PMID>
  </reference>
  <reference>
    <citation>de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002 Feb;77(2):357-62.</citation>
    <PMID>11821097</PMID>
  </reference>
  <reference>
    <citation>Fréour T, Mirallié S, Colombel A, Bach-Ngohou K, Masson D, Barrière P. Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Ann Endocrinol (Paris). 2006 Dec;67(6):567-74. Review.</citation>
    <PMID>17194966</PMID>
  </reference>
  <reference>
    <citation>Gleicher N, Kim A, Weghofer A, Barad DH. Toward a better understanding of functional ovarian reserve: AMH (AMHo) and FSH (FSHo) hormone ratios per retrieved oocyte. J Clin Endocrinol Metab. 2012 Mar;97(3):995-1004. doi: 10.1210/jc.2011-2403. Epub 2011 Dec 14.</citation>
    <PMID>22170712</PMID>
  </reference>
  <reference>
    <citation>Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010 Feb;93(3):855-64. doi: 10.1016/j.fertnstert.2008.10.042. Epub 2008 Nov 30.</citation>
    <PMID>19046583</PMID>
  </reference>
  <reference>
    <citation>Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil Steril. 2008 Sep;90(3):737-43. Epub 2007 Oct 17.</citation>
    <PMID>17923131</PMID>
  </reference>
  <reference>
    <citation>Panchal S, Nagori C. Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve. J Hum Reprod Sci. 2012 Sep;5(3):274-8. doi: 10.4103/0974-1208.106340.</citation>
    <PMID>23531919</PMID>
  </reference>
  <reference>
    <citation>Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005 Feb;45(1):20-4.</citation>
    <PMID>15730360</PMID>
  </reference>
  <reference>
    <citation>van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002 Dec;17(12):3065-71.</citation>
    <PMID>12456604</PMID>
  </reference>
  <reference>
    <citation>Biasoni V, Patriarca A, Dalmasso P, Bertagna A, Manieri C, Benedetto C, Revelli A. Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF. Reprod Biol Endocrinol. 2011 Aug 9;9:112. doi: 10.1186/1477-7827-9-112.</citation>
    <PMID>21824441</PMID>
  </reference>
  <reference>
    <citation>Choi MH, Yoo JH, Kim HO, Cha SH, Park CW, Yang KM, Song IO, Koong MK, Kang IS. Serum anti-Müllerian hormone levels as a predictor of the ovarian response and IVF outcomes. Clin Exp Reprod Med. 2011 Sep;38(3):153-8. doi: 10.5653/cerm.2011.38.3.153. Epub 2011 Sep 30.</citation>
    <PMID>22384435</PMID>
  </reference>
  <reference>
    <citation>Elgindy EA, El-Haieg DO, El-Sebaey A. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril. 2008 Jun;89(6):1670-6. Epub 2007 Jul 20.</citation>
    <PMID>17658520</PMID>
  </reference>
  <reference>
    <citation>Honnma H, Baba T, Sasaki M, Hashiba Y, Oguri H, Fukunaga T, Endo T, Asada Y. Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization. J Assist Reprod Genet. 2012 Feb;29(2):117-25. doi: 10.1007/s10815-011-9675-9. Epub 2011 Nov 16.</citation>
    <PMID>22086616</PMID>
  </reference>
  <reference>
    <citation>La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007 Mar;22(3):766-71. Epub 2006 Oct 27.</citation>
    <PMID>17071823</PMID>
  </reference>
  <reference>
    <citation>Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005 Oct;112(10):1384-90.</citation>
    <PMID>16167941</PMID>
  </reference>
  <reference>
    <citation>Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, Laing I. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009 Nov;92(5):1586-93. doi: 10.1016/j.fertnstert.2008.08.127. Epub 2008 Oct 18.</citation>
    <PMID>18930213</PMID>
  </reference>
  <reference>
    <citation>Singh N, Malik E, Banerjee A, Chosdol K, Sreenivas V, Mittal S. &quot;Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients&quot;: A First Pilot Study in the Indian Population. J Obstet Gynaecol India. 2013 Aug;63(4):268-72. doi: 10.1007/s13224-012-0318-6. Epub 2013 Feb 22.</citation>
    <PMID>24431654</PMID>
  </reference>
  <reference>
    <citation>Wu CH, Chen YC, Wu HH, Yang JG, Chang YJ, Tsai HD. Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet. 2009 Jul;26(7):383-9. doi: 10.1007/s10815-009-9332-8.</citation>
    <PMID>19768530</PMID>
  </reference>
  <reference>
    <citation>Alviggi C, Humaidan P, Ezcurra D. Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. Reprod Biol Endocrinol. 2012 Feb 6;10:9. doi: 10.1186/1477-7827-10-9. Review.</citation>
    <PMID>22309877</PMID>
  </reference>
  <reference>
    <citation>Bosch E, Ezcurra D. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. Reprod Biol Endocrinol. 2011 Jun 21;9:82. doi: 10.1186/1477-7827-9-82.</citation>
    <PMID>21693025</PMID>
  </reference>
  <reference>
    <citation>Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011 Jan-Feb;17(1):46-54. doi: 10.1093/humupd/dmq034. Epub 2010 Jul 28. Review.</citation>
    <PMID>20667894</PMID>
  </reference>
  <reference>
    <citation>Fleming R, Broekmans F, Calhaz-Jorge C, Dracea L, Alexander H, Nyboe Andersen A, Blockeel C, Jenkins J, Lunenfeld B, Platteau P, Smitz J, de Ziegler D. Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation? Reprod Biomed Online. 2013 May;26(5):431-9. doi: 10.1016/j.rbmo.2012.02.027. Epub 2013 Feb 4. Review.</citation>
    <PMID>23507133</PMID>
  </reference>
  <reference>
    <citation>La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014 Jan-Feb;20(1):124-40. doi: 10.1093/humupd/dmt037. Epub 2013 Sep 29. Review.</citation>
    <PMID>24077980</PMID>
  </reference>
  <reference>
    <citation>Martínez F, Clua E, Carreras O, Tur R, Rodríguez I, Barri PN. Is AMH useful to reduce low ovarian response to GnRH antagonist protocol in oocyte donors? Gynecol Endocrinol. 2013 Aug;29(8):754-7. doi: 10.3109/09513590.2013.801443. Epub 2013 Jun 12.</citation>
    <PMID>23758138</PMID>
  </reference>
  <reference>
    <citation>Nakhuda GS, Douglas NC, Thornton MH, Guarnaccia MM, Lobo R, Sauer MV. Anti-Müllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. Reprod Biomed Online. 2010 Jan;20(1):42-7. doi: 10.1016/j.rbmo.2009.10.009. Epub 2009 Oct 30.</citation>
    <PMID>20158986</PMID>
  </reference>
  <reference>
    <citation>Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum Reprod. 2007 Sep;22(9):2414-21. Epub 2007 Jul 18.</citation>
    <PMID>17636277</PMID>
  </reference>
  <reference>
    <citation>Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A, Nardo LG. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011 Sep;26(9):2353-62. doi: 10.1093/humrep/der182. Epub 2011 Jun 13.</citation>
    <PMID>21672928</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimullerian Hormone</keyword>
  <keyword>In vitro fertilization</keyword>
  <keyword>Medications</keyword>
  <keyword>Dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

